| NCT ID | NCT03505216 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bern |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2017-06-06 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2017-06-06 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Swiss Paediatric Airway Cohort (SPAC) is a national, prospective clinical cohort of children and adolescents who visit physicians in Switzerland for recurrent wheeze, cough, and exercise- or sleep-related respiratory problems. SPAC aims to answer important questions on clinical phenotypes, prognosis, diagnosis and treatment. SPAC is part of routine care, and only clinically indicated investigations are done. The comprehensive baseline assessment includes a detailed questionnaire to families, plus test results, diagnoses and treatments from hospital records. Follow-up is via monthly questionnaires the first 12 months and thereafter annual questionnaires to families, and data from follow-up visits. Currently, 4344 patients from 10 clinics and hospitals in Switzerland (Aarau, Basel, Bern, Chur, Horgen, Lausanne, Luzern, St. Gallen, Worb, Zurich) have been enrolled. SPAC provides real-life data on children visiting the Swiss health care system for common respiratory problems. It will provide a research platform for health services research, and for nested clinical and transitional studies. Publications and plain language summaries are listed on the study website: https://www.spac-study.ch/publikationen/
Eligibility Criteria
Inclusion Criteria: * Children and adolescents aged 0-16 years * Resident in Switzerland * Seen in a paediatric pulmonary outpatient clinic due to respiratory problems * Parents and patients above age 14 must be able to sign an informed consent form Exclusion Criteria: Prior diagnosis of cystic fibrosis, primary ciliary dyskinesia, severe heart disease, oncological disease, neuromuscular disease or severe disability
Contact & Investigator
Claudia E Kuehni, Prof.
STUDY DIRECTOR
Institute of Social and Preventive Medicine
Frequently Asked Questions
Who can join the NCT03505216 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 16 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03505216 currently recruiting?
Yes, NCT03505216 is actively recruiting participants. Contact the research team at claudia.kuehni@unibe.ch for enrollment information.
Where is the NCT03505216 trial being conducted?
This trial is being conducted at Vienna, Austria, Aarau, Switzerland, Basel, Switzerland, Bern, Switzerland and 8 additional locations.
Who is sponsoring the NCT03505216 clinical trial?
NCT03505216 is sponsored by University of Bern. The principal investigator is Claudia E Kuehni, Prof. at Institute of Social and Preventive Medicine. The trial plans to enroll 6,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.